Promising Potential of Merus’s Petosemtamab in HNSCC: A Buy Recommendation
Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Merus (MRUS – Research Report) yesterday and set a price target of ...
Merus (MRUS): FDA Approval and Speculative Future in Cancer Therapy
We recently published a list of Jim Cramer’s Lightning Rounds: 12 Stocks Under the Spotlight. In this article, we are going ...
Citigroup Issues Positive Forecast for Merus (NASDAQ:MRUS) Stock Price
Merus (NASDAQ:MRUS – Get Free Report) had its price target hoisted by research analysts at Citigroup from $89.00 to $97.00 in ...
Merus Scores Its First FDA Approval For Lung Cancer Drug
Bizengri (zenocutuzumab-zbco) as the first and only treatment indicated for adults with pancreatic adenocarcinoma or ...
FiercePharma7d
FDA signs off on Merus' first-in-class NRG1+ cancer drug Bizengri after brief delay
Merus’ week keeps getting better. Days after securing a long-awaited commercialization partner for its zenocutuzumab, the ...
Merus’s Promising Prospects: Buy Rating Highlighted by Positive Data on Peto’s Efficacy in HNSCC
Analyst Ami Fadia of Needham maintained a Buy rating on Merus (MRUS – Research Report), retaining the price target of $85.00.Pick the best ...
Merus (NASDAQ:MRUS) Given “Buy” Rating at Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of Merus (NASDAQ:MRUS – Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $85.00 price target on the ...
Cramer's Lightning Round: Merus is ‘very speculative'
Mad Money” host Jim Cramer rings the lightning round bell, which means he’s giving his answers to callers’ stock questions at ...
US FDA approves Merus' therapy to treat lung, pancreatic cancers
The U.S. Food and Drug Administration has approved Merus NV's therapy that targets a particular gene, expanding treatment ...
GlobalData on MSN6d
Merus’ Bizengri granted FDA accelerated approval to treat NRG1+ cancers
The FDA has granted accelerated approval to Bizengri in the treatment of advanced, unresectable NG1+ lung and pancreatic ...
Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus' Pipeline
Merus N.V. (NASDAQ:MRUS) and Partner Therapeutics Inc, a private biotechnology company focused on hematology and oncology, ...
FierceBiotech9d
Merus' head and neck cancer candidate bolsters 'best-in-disease' profile with new data drop: analyst
With new data on petosemtamab set to be presented at the European Society for Medical Oncology Asia Congress, Merus believes ...